Trifluridine and Tipiracil Tablets (TrifluridineTipiracil) is an anti-cancer targeted drug. While exerting therapeutic effects, it is also accompanied by a series of potential side effects and medication risks.

What Are the Side Effects of Trifluridine and Tipiracil Tablets (TrifluridineTipiracil)?

Hematological Toxic Reactions

Neutropenia (incidence rate: 67%, of which Grade 3-4 accounts for 38%).

Anemia (incidence rate: 77%, of which Grade 3-4 accounts for 18%).

Thrombocytopenia (incidence rate: 42%, of which Grade 3-4 accounts for 5%).

When Combined with Bevacizumab Therapy

Neutropenia (incidence rate: 80%, of which Grade 3-4 accounts for 52%).

Hemoglobin decrease (incidence rate: 68%, of which Grade 3-4 accounts for 5%).

Gastrointestinal Adverse Reactions

Nausea (48% in monotherapy, 37% in combination therapy).

Diarrhea (32% in monotherapy, 21% in combination therapy).

Vomiting (28% in monotherapy, 19% in combination therapy).

Abdominal pain (21% in monotherapy, 20% in combination therapy).

Systemic Reactions

Weakness/fatigue (52% in monotherapy, 45% in combination therapy).

Decreased appetite (39% in monotherapy, 20% in combination therapy).

Fever (incidence rate: 19%).

Severe Side Effects of Trifluridine and Tipiracil Tablets (TrifluridineTipiracil) That Require High Alert

Severe Myelosuppression

Grade 3 and above neutropenia reaches 38% in monotherapy and 52% in combination therapy.

Special attention should be paid to neutropenic infections (incidence rate: 3%); in clinical trials, 0.3% of patients died of neutropenic sepsis.

Embryo-Fetal Toxicity

Animal experiments have shown that embryonic lethality and embryonic toxicity occur in pregnant rats after drug administration.

Women of childbearing age need to take effective contraceptive measures during treatment and within 6 months after the last dose.

Precautions for Taking Trifluridine and Tipiracil Tablets (TrifluridineTipiracil)

Requirements for Blood Routine Monitoring

A complete blood cell count test must be performed before each cycle and on the 15th day of the cycle.

Special Administration Guidelines

There is no need to make up for the missed dose after vomiting.

Personnel who come into contact with the tablets must wear gloves.

Tablets must be discarded 30 days after being removed from the original packaging.

Key Points for Patient Education

Patients need to understand and report signs of infection (fever, chills, etc.) in a timely manner.

Seek medical attention immediately if severe or persistent nausea, vomiting, or diarrhea occurs.

Strictly comply with contraceptive requirements; male patients need to use condoms during treatment and within 3 months after the last dose.